Liu Xianqiang, Xi Xiaowei, Xu Shengshan, Chu Hongyu, Hu Penghui, Li Dong, Zhang Bin, Liu Hejie, Jiang Tianxiao, Lu Zhuming
Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Graduate School, Medical School of Chinese PLA, Beijing, China.
Front Immunol. 2024 Dec 12;15:1507501. doi: 10.3389/fimmu.2024.1507501. eCollection 2024.
Lung cancer continues to be a major contributor to cancer-related deaths globally. Recent advances in immunotherapy have introduced promising treatments targeting T cell functionality. Central to the efficacy of these therapies is the role of T cells, which are often rendered dysfunctional due to continuous antigenic stimulation in the tumor microenvironment-a condition referred to as T cell exhaustion. This review addresses the critical challenge of T cell exhaustion in non-small cell lung cancer (NSCLC), offering a detailed examination of its molecular underpinnings and the resultant therapeutic ineffectiveness. We synthesize current knowledge on the drivers of T cell exhaustion, evaluate emerging strategies for its reversal, and explore the potential impact of these insights for enhancing the clinical efficacy of immunotherapies. By consolidating reported clinical trials and preclinical studies, this article highlights innovative approaches to modulate immune responses and improve patient outcomes, thus providing a roadmap for future research and therapeutic development in lung cancer immunotherapy.
肺癌仍然是全球癌症相关死亡的主要原因。免疫疗法的最新进展带来了针对T细胞功能的有前景的治疗方法。这些疗法疗效的核心是T细胞的作用,由于肿瘤微环境中持续的抗原刺激,T细胞常常功能失调,这种情况被称为T细胞耗竭。本综述阐述了非小细胞肺癌(NSCLC)中T细胞耗竭这一关键挑战,详细探讨了其分子基础以及由此导致的治疗无效性。我们综合了关于T细胞耗竭驱动因素的现有知识,评估了逆转T细胞耗竭的新兴策略,并探讨了这些见解对提高免疫疗法临床疗效的潜在影响。通过整合已报道的临床试验和临床前研究,本文强调了调节免疫反应和改善患者预后的创新方法,从而为肺癌免疫疗法的未来研究和治疗发展提供了路线图。